Rana McKay, MD, of the University of California San Diego, San Diego, CA, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. In the Phase II, open-label, single-arm study (NCT02724878), Dr Rana McKay and colleagues investigated the efficacy and safety of the combined use of atezolizumab and bevacizumab in non-clear cell and sarcomatoid differentiation RCC. She reports that promising anti-tumor activity was shown in the treated patients, in addition to a tolerable safety profile.